HRP20230985T1 - Farmaceutske formulacije pegiliranih liposoma i faktora koagulacije krvi - Google Patents
Farmaceutske formulacije pegiliranih liposoma i faktora koagulacije krvi Download PDFInfo
- Publication number
- HRP20230985T1 HRP20230985T1 HRP20230985TT HRP20230985T HRP20230985T1 HR P20230985 T1 HRP20230985 T1 HR P20230985T1 HR P20230985T T HRP20230985T T HR P20230985TT HR P20230985 T HRP20230985 T HR P20230985T HR P20230985 T1 HRP20230985 T1 HR P20230985T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- pharmaceutical preparation
- optionally
- amphipathic lipid
- colloidal particle
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 5
- 102000015081 Blood Coagulation Factors Human genes 0.000 title 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 title 1
- 239000003114 blood coagulation factor Substances 0.000 title 1
- 229940019700 blood coagulation factors Drugs 0.000 title 1
- 239000002502 liposome Substances 0.000 title 1
- 239000002245 particle Substances 0.000 claims 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims 10
- 150000002632 lipids Chemical class 0.000 claims 9
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 6
- 229920001223 polyethylene glycol Polymers 0.000 claims 6
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 claims 5
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 229960000182 blood factors Drugs 0.000 claims 3
- 229920001477 hydrophilic polymer Polymers 0.000 claims 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 2
- ZGCHLAJIRWDGFE-UHFFFAOYSA-N 1-aminopropane-1,1-diol Chemical compound CCC(N)(O)O ZGCHLAJIRWDGFE-UHFFFAOYSA-N 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 108010054218 Factor VIII Proteins 0.000 claims 1
- 102000001690 Factor VIII Human genes 0.000 claims 1
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4866—Protein C (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (12)
1. Farmaceutski pripravak za uporabu u liječenju pacijenta koji boluje od hemofilije A koja sadrži faktor krvi VIII i koloidnu česticu, pri čemu koloidna čestica sadrži oko 0.5 do 20 molnih postotaka amfipatskog lipida derivatiziranog sa biokompatibilnim hidrofilnim polimerom, pri čemu je koloidna čestica suštinski neutralna i polimer u suštini ne nosi neto naboj, pri čemu krvni faktor nije inkapsuliran u navedenoj koloidnoj čestici, pri čemu se pripravak primjenjuje subkutano i pri čemu se ponovljena subkutana primjena farmaceutskog pripravka izvodi prije nego što se koncentracija farmaceutske kompozicije u krvi smanjuje do subterapeutskih nivoa.
2. Farmaceutski pripravak za uporabu prema zahtjevu 1, naznačen time što koloidna čestica ima srednji promjer čestice između oko 0.03 do oko 0.4 mikrona (µm); izborno pri čemu koloidna čestica ima srednji promjer čestice od približno 0.1 mikrona (µm).
3. Farmaceutski pripravak za uporabu prema zahtjevu 1 ili zahtjevu 2, naznačen time što navedeni amfipatski lipid je fosfolipid iz prirodnih ili sintetičkih izvora; izborno pri čemu navedeni amfipatski lipid je fosfatidiletanolamin (PE).
4. Farmaceutski pripravak za uporabu prema zahtjevu 1 ili zahtjevu 2, naznačen time što navedeni amfipatski lipid je nenabijeni lipopolimer povezan sa karbamatom; izborno pri čemu navedeni amfipatski lipid je aminopropandiol distearoil (DS).
5. Farmaceutski pripravak za uporabu prema zahtjevu 1, naznačen time što navedene koloidne čestice dalje sadrže drugi amfipatski lipid dobiven bilo iz prirodnih ili sintetičkih izvora; izborno pri čemu navedeni drugi amfipatski lipid je fosfatidilholin.
6. Farmaceutski pripravak za uporabu prema zahtjevu 5, naznačen time što koloidna čestica sadrži palmitoil-oleoil fosfatidil kolin (POPC) i 1,2-distearoil-sn-glicero-3-fosfoetanol-amin (DSPE) u odnosu (POPC:DSPE) od 85 do 99:15 do 1; izborno pri čemu odnos POPC:DSPE je od 90 do 99:10 do 1; izborno pri čemu odnos POPC:DSPE je 97:3.
7. Farmaceutski pripravak za uporabu prema zahtjevu 5, naznačen time što je kolesterol dodan pripravku.
8. Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 1 do 7, naznačen time što je navedeni biokompatibilni hidrofilni polimer izabran iz grupe koja se sastoji od polialkiletara, polimliječnih kiselina i poliglikolnih kiselina; izborno pri čemu navedeni biokompatibilni hidrofilni polimer je polietilen glikol.
9. Farmaceutski pripravak za uporabu prema zahtjevu 8, naznačen time što polietilen glikol ima molekulsku težinu između oko 500 do oko 5000 daltona; izborno pri čemu polietilen glikol ima molekulsku težinu od približno 2000 daltona.
10. Farmaceutski pripravak za uporabu prema zahtjevu 8 ili zahtjevu 9, naznačen time što derivatizirani amfipatski lipid je 1,2-distearoil-sn-glicero-3-fosfoetanol-amin-N-[poli-(etilenglikol)]; izborno pri čemu derivatizirani amfipatski lipid je 1,2-distearoil-sn-glicero-3-fosfoetanol-amin-N-[poli-(etilenglikol)-2000] (DSPE-PEG 2000).
11. Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 1 do 10, naznačen time što pripravak dodatno sadrži još jedan terapeutski aktivan spoj.
12. Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 1 do 11, naznačen time što je navedeni pacijent razvio antitijela na faktor krvi.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1417589.7A GB201417589D0 (en) | 2014-10-06 | 2014-10-06 | Pharmaceutical Formulations |
| EP15775444.1A EP3204034B9 (en) | 2014-10-06 | 2015-10-06 | Pharmaceutical formulations of pegylated liposomes and blood coagulation factors |
| PCT/EP2015/073003 WO2016055447A1 (en) | 2014-10-06 | 2015-10-06 | Pharmaceutical formulations of pegylated liposomes and blood coagulation factors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230985T1 true HRP20230985T1 (hr) | 2023-12-08 |
Family
ID=51946871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230985TT HRP20230985T1 (hr) | 2014-10-06 | 2015-10-06 | Farmaceutske formulacije pegiliranih liposoma i faktora koagulacije krvi |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20170304203A1 (hr) |
| EP (1) | EP3204034B9 (hr) |
| JP (3) | JP2017531659A (hr) |
| AU (1) | AU2015330102B2 (hr) |
| BR (1) | BR112017007031A2 (hr) |
| CA (1) | CA2994891C (hr) |
| ES (1) | ES2954134T3 (hr) |
| GB (1) | GB201417589D0 (hr) |
| HR (1) | HRP20230985T1 (hr) |
| HU (1) | HUE063656T2 (hr) |
| MX (1) | MX2017004378A (hr) |
| PL (1) | PL3204034T3 (hr) |
| RS (1) | RS64461B1 (hr) |
| RU (1) | RU2737291C2 (hr) |
| WO (1) | WO2016055447A1 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201417589D0 (en) * | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
| WO2017204896A1 (en) * | 2016-05-26 | 2017-11-30 | Becton, Dickinson And Company | Methods and devices for liposome preparation by centrifugation |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US6326353B1 (en) | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
| JPH09501169A (ja) | 1993-08-06 | 1997-02-04 | オパーバス ホールディング ビー ヴィ | 小胞に生体高分子物質を高度に充填する方法 |
| IL113010A (en) * | 1994-03-31 | 1999-10-28 | Pharmacia & Upjohn Ab | Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| US6156337A (en) * | 1994-07-08 | 2000-12-05 | Opperbas Holding B.V. | Method for high loading of vesicles with biopolymeric substances |
| US6310183B1 (en) * | 1997-09-10 | 2001-10-30 | Novo Nordisk A/S | Coagulation factor VIIa composition |
| PT1079805E (pt) * | 1998-04-27 | 2005-03-31 | Opperbas Holding Bv | Composicao farmaceutica compreendendo factor viii e lipossomas neutros |
| ATE317869T1 (de) | 1999-07-14 | 2006-03-15 | Alza Corp | Neutrales lipopolymer und liposomale zusammensetzungen daraus |
| AU2001256148A1 (en) * | 2000-05-03 | 2001-11-12 | Novo-Nordisk A/S | Subcutaneous administration of coagulation factor vii |
| US20030232075A1 (en) | 2002-05-06 | 2003-12-18 | University Of Minnesota, A Minnesota Corporation | Compositions for producing factor Xa |
| ES2307009T3 (es) * | 2003-04-15 | 2008-11-16 | Opperbas Holding B.V. | Composicion farmaceutica que contiene proteinas y/o polipeptidos y particulas coloidales. |
| EP1898939A2 (en) | 2005-06-29 | 2008-03-19 | The Research Foundation of State of University Of New York at Buffalo | Compositions and methods for less immunogenic pr0tein-lip1d complexes |
| EP2099475B1 (en) * | 2007-01-03 | 2016-08-24 | Novo Nordisk Health Care AG | Subcutaneous administration of coagulation factor viia-related polypeptides |
| WO2009051701A2 (en) | 2007-10-15 | 2009-04-23 | Wake Forest University Health Sciences | Methods and compositions for printing biologically compatible nanotube composites of autologous tissue |
| WO2010140061A2 (en) | 2009-06-03 | 2010-12-09 | John Charles Mayo | Formulations for the treatment of deep tissue pain |
| DE112010003355T5 (de) | 2009-08-21 | 2012-07-12 | Targeted Delivery Technologies Ltd. | Veskuläre Formulierungen |
| GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| GB201007357D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
| AR082803A1 (es) * | 2010-09-01 | 2013-01-09 | Portola Pharm Inc | Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p |
| GB2516388A (en) | 2012-04-16 | 2015-01-21 | Cantab Biopharmaceuticals Patents Ltd | Optimised subcutaneous therapeutic agents |
| GB201417589D0 (en) * | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
-
2014
- 2014-10-06 GB GBGB1417589.7A patent/GB201417589D0/en not_active Ceased
-
2015
- 2015-10-06 ES ES15775444T patent/ES2954134T3/es active Active
- 2015-10-06 HU HUE15775444A patent/HUE063656T2/hu unknown
- 2015-10-06 JP JP2017518466A patent/JP2017531659A/ja active Pending
- 2015-10-06 US US15/517,148 patent/US20170304203A1/en not_active Abandoned
- 2015-10-06 CA CA2994891A patent/CA2994891C/en active Active
- 2015-10-06 RU RU2017115831A patent/RU2737291C2/ru active
- 2015-10-06 PL PL15775444.1T patent/PL3204034T3/pl unknown
- 2015-10-06 BR BR112017007031A patent/BR112017007031A2/pt active Search and Examination
- 2015-10-06 AU AU2015330102A patent/AU2015330102B2/en active Active
- 2015-10-06 RS RS20230695A patent/RS64461B1/sr unknown
- 2015-10-06 EP EP15775444.1A patent/EP3204034B9/en active Active
- 2015-10-06 MX MX2017004378A patent/MX2017004378A/es unknown
- 2015-10-06 HR HRP20230985TT patent/HRP20230985T1/hr unknown
- 2015-10-06 WO PCT/EP2015/073003 patent/WO2016055447A1/en active Application Filing
-
2018
- 2018-08-01 US US16/052,300 patent/US11484499B2/en active Active
-
2020
- 2020-07-30 JP JP2020129101A patent/JP2020183446A/ja active Pending
-
2022
- 2022-10-20 JP JP2022168146A patent/JP2023002687A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016055447A1 (en) | 2016-04-14 |
| AU2015330102B2 (en) | 2021-01-28 |
| CA2994891A1 (en) | 2016-04-14 |
| EP3204034C0 (en) | 2023-06-07 |
| US20190060235A1 (en) | 2019-02-28 |
| PL3204034T3 (pl) | 2023-11-06 |
| JP2017531659A (ja) | 2017-10-26 |
| RU2017115831A (ru) | 2018-11-14 |
| CA2994891C (en) | 2023-04-04 |
| MX2017004378A (es) | 2018-02-09 |
| JP2020183446A (ja) | 2020-11-12 |
| RU2737291C2 (ru) | 2020-11-26 |
| US20170304203A1 (en) | 2017-10-26 |
| ES2954134T3 (es) | 2023-11-20 |
| AU2015330102A1 (en) | 2017-05-25 |
| US11484499B2 (en) | 2022-11-01 |
| EP3204034A1 (en) | 2017-08-16 |
| JP2023002687A (ja) | 2023-01-10 |
| BR112017007031A2 (pt) | 2018-01-30 |
| RU2017115831A3 (hr) | 2019-05-06 |
| EP3204034B9 (en) | 2023-10-04 |
| EP3204034B1 (en) | 2023-06-07 |
| RS64461B1 (sr) | 2023-09-29 |
| GB201417589D0 (en) | 2014-11-19 |
| HUE063656T2 (hu) | 2024-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pei et al. | Drug delivery to macrophages: challenges and opportunities | |
| Ferreira et al. | pH-sensitive liposomes for drug delivery in cancer treatment | |
| JP6751424B2 (ja) | ダイズホスファチジルセリンで作られたコクリエート | |
| JP6535281B2 (ja) | 関節炎の処置方法 | |
| JP2018184470A5 (hr) | ||
| US20170281541A1 (en) | Liposome-based mucus-penetrating particles for mucosal delivery | |
| CN108024960A (zh) | 含有阴离子药物的药物组合物及其制备方法 | |
| US20170072033A1 (en) | Liposomal compositions for mucosal delivery | |
| JP2017052790A (ja) | ｓＰＬＡ２加水分解性リポソームを含む医薬組成物 | |
| US20080026049A1 (en) | Liposomal compositions for parenteral delivery of agents | |
| AU2015352688A1 (en) | Pharmaceutical composition, preparation and uses thereof | |
| AU2015206628A1 (en) | Liposome compositions encapsulating modified cyclodextrin complexes and uses thereof | |
| Camilo et al. | Lipid vesicles: Applications, principal components and methods used in their formulations. A review | |
| HRP20230985T1 (hr) | Farmaceutske formulacije pegiliranih liposoma i faktora koagulacije krvi | |
| Mozafari et al. | An overview of liposome-derived nanocarrier technologies | |
| Li et al. | Colistin-entrapped liposomes driven by the electrostatic interaction: mechanism of drug loading and in vivo characterization | |
| JP2018535952A5 (hr) | ||
| CA2595485A1 (en) | Liposomal compositions for parenteral delivery of statins | |
| CN113041345B (zh) | 一种纳米类毒素疫苗及其用途 | |
| JP7463306B2 (ja) | 関節内ステロイドの合併症を軽減する方法 | |
| JP2017531659A5 (hr) | ||
| EP3017823B1 (en) | Lipid nanoparticle of polymyxin | |
| CN104248768B (zh) | 靶向中枢神经系统的纳米药物载体 | |
| WO2003022250A2 (en) | Unilamellar vesicles stabilized with short chain hydrophilic polymers | |
| TW202220668A (zh) | 用於疼痛控制之關節內皮質類固醇的藥學組成物 |